The GLP-1 Advantage: Ensuring Efficacy and Functionality With Advanced Drug Delivery Solutions

GLP-1 receptor agonist therapies for obesity and type 2 diabetes represent one of the highest-growth segments in injectable drug delivery — yet their chemically sensitive peptide structures, self-administration requirements, and mass-market scale introduce packaging challenges that demand precise material selection, optimized component design, and rigorous contamination control across the full development and commercial lifecycle. This on-demand webinar provides a structured technical framework for pharmaceutical packaging teams developing GLP-1 therapies in pen injector cartridge and prefilled syringe formats. The session begins with the molecular sensitivity of GLP-1 peptides — susceptibility to aggregation from extractables exposure, oxidation from reactive leachables, and hydrophobic destabilization — and the material requirements this imposes across compound purity, chemical compatibility, physical sealing properties, and biocompatibility compliance. FM457's ultra-low extractables BIMS formulation is presented as the primary compound solution, with NeoFlex™ fluoropolymer spray coating providing an additional inert barrier for the most sensitive formulations. DuraCoat™ combiseals are evaluated for their role in eliminating lacquered aluminum particulate generation — with supporting customer data confirming 10–100x reductions in airborne particle counts versus standard lacquered combiseals. A detailed case study contrasts a standard Advanced-tier 3 mL cartridge plunger against the optimized FirstLine® V9520 design — demonstrating how undercut trim edge geometry, asymmetric orientability, cone dead-volume reduction, and stricter FirstLine® bioburden (0.2 CFU/product) and endotoxin (0.1 EU/product) specifications translate into stable injection times, lower reject rates, and improved CCI. The session concludes with EU GMP Annex 1 compliance strategies, covering intrinsic and extrinsic particulate origins, the role of coatings in minimizing silicone-derived particles, validated washing and sterilization processes, and RTP bag configurations for Annex 1-compliant aseptic transfer.